RHJA
ANIP icon

Rice Hall James & Associates’s ANI Pharmaceuticals ANIP Stock Holding History

Rice Hall James & Associates’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Buy
28,562
+1,746
+7% +$140K 0.12% 166
2026
Q1 		$2.06M Hold
26,816
– – 0.11% 160
2025
Q4 		$2.12M Sell
26,816
-4,681
-15% -$405K 0.12% 160
2025
Q3 		$2.89M Sell
31,497
-22,482
-42% -$1.83M 0.16% 131
2025
Q2 		$3.52M Sell
53,979
-4,610
-8% -$300K 0.19% 121
2025
Q1 		$3.92M Sell
58,589
-379
-0.6% -$22.6K 0.23% 94
2024
Q4 		$3.26M Sell
58,968
-1,407
-2% -$80.8K 0.18% 130
2024
Q3 		$3.6M Sell
60,375
-297
-0.5% -$18.1K 0.19% 117
2024
Q2 		$3.86M Sell
60,672
-4,162
-6% -$270K 0.23% 96
2024
Q1 		$4.48M Sell
64,834
-86
-0.1% -$5.19K 0.26% 87
2023
Q4 		$3.58M Sell
64,920
-3,283
-5% -$181K 0.21% 113
2023
Q3 		$3.96M Buy
68,203
+20,760
+44% +$1.2M 0.25% 93
2023
Q2 		$2.55M Buy
+47,443
New +$2.1M 0.14% 155
2020
Q3 		– Sell
-27,526
Closed -$890K – 274
2020
Q2 		$890K Sell
27,526
-200
-0.7% -$7.17K 0.04% 216
2020
Q1 		$1.13M Sell
27,726
-217
-0.8% -$11.5K 0.06% 190
2019
Q4 		$1.72M Sell
27,943
-706
-2% -$46.8K 0.06% 187
2019
Q3 		$2.09M Buy
28,649
+2,335
+9% +$175K 0.07% 164
2019
Q2 		$2.16M Sell
26,314
-1,600
-6% -$114K 0.07% 168
2019
Q1 		$1.97M Sell
27,914
-1,225
-4% -$72.1K 0.06% 192
2018
Q4 		$1.31M Buy
29,139
+2,947
+11% +$154K 0.05% 230
2018
Q3 		$1.48M Sell
26,192
-6,186
-19% -$379K 0.05% 227
2018
Q2 		$2.16M Buy
+32,378
New +$2.02M 0.08% 191
2017
Q2 		– Sell
-32,426
Closed -$1.6M – 290
2017
Q1 		$1.6M Sell
32,426
-700
-2% -$39.3K 0.08% 218
2016
Q4 		$2.01M Sell
33,126
-200
-0.6% -$12.2K 0.1% 191
2016
Q3 		$2.21M Buy
+33,326
New +$2.08M 0.12% 164

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rice Hall James & Associates's ANIP Position: Q2 2026 in Review

Rice Hall James & Associates increased its ANI Pharmaceuticals (ANIP) stake by 6.5% in Q2 2026, buying an estimated $140K and bringing the position to 28,562 shares worth $2.36M. The position accounts for 0.12% of the portfolio, ranked #166.

Rice Hall James & Associates first reported a position in ANIP in Q3 2016 and has held it in 25 quarters since. The position peaked at $4.48M in Q1 2024. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Rice Hall James & Associates held 28,562 shares of ANI Pharmaceuticals worth $2.36M as of Q2 2026.
  • Rice Hall James & Associates bought 1,746 ANI Pharmaceuticals shares in Q2 2026, an estimated $140K.
  • ANI Pharmaceuticals made up 0.12% of Rice Hall James & Associates's portfolio in Q2 2026, its #166 holding.
  • Rice Hall James & Associates first reported a position in ANI Pharmaceuticals in Q3 2016 and has held it in 25 quarters since.
  • Rice Hall James & Associates's ANI Pharmaceuticals position peaked at $4.48M in Q1 2024.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.